Cabozantinib

Brand names: Omcazio · Active ingredient: Cabozantinib Laurylsulfate

In short: OMCAZIO is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). OMCAZIO, in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced RCC.

Forms & strengthsCapsules: 34.5 mg: Opaque white hard gelatin capsules with black imprint "HP 34.5" on capsule body. 23 mg: Opaque blue cap and opaque white body, hard gelatin capsules with a black imprint "HP 23" on capsule body. …
LabelHanda Pharma
Label updatedNov 16, 2026

What is Cabozantinib used for?

OMCAZIO is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC).

OMCAZIO, in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced RCC.

OMCAZIO is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

OMCAZIO is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET).

âš  Boxed warning (FDA's strongest warning)

OMCAZIO is not substitutable on a mg-to-mg basis with other cabozantinib products. Inappropriate substitution or incorrect conversion of OMCAZIO capsules for another cabozantinib product can increase the risk of serious adverse reactions. Confirm that the intended cabozantinib product at the intended dosage and strength is being prescribed and dispensed. (

2.1,

2.3,

5.1)

Cabozantinib dosage

Cabozantinib is available in multiple dosage forms and strengths. Recommended dosages depend on the specific cabozantinib product prescribed.

OMCAZIO is

NOTsubstitutable on a mg-to-mg basis with other cabozantinib products

.

To avoid medication errors, including overdosage or underdosage, prescribe the recommended dosage specific for OMCAZIO

.

OMCAZIO may be taken with or without food

.

Swallow OMCAZIO capsules whole. Do not crush, chew, or open OMCAZIO capsules.

If a dose of OMCAZIO is missed, take the missed dose as soon as possible. If a dose is missed by more than 12 hours, skip the missed dose and take the next dose at the scheduled time. Do not take 2 doses at the same time to make up for the missed dose.

Stop OMCAZIO at least 3 weeks prior to scheduled surgery, including dental surgery to reduce the risk of hemorrhage. Do not administer OMCAZIO for at least 2 weeks after major surgery and until adequate wound healing

.

The recommended dosages of OMCAZIO are presented in Table 1.

Indication | Recommended Dosage | Duration

Renal Cell Carcinoma | Single Agent

34.5 mg orally once daily | Until disease progression or unacceptable toxicity

Combination Therapy

23 mg orally once daily in combination with nivolumab or nivolumab and hyaluronidase-nvhy

Refer to the Prescribing Information for nivolumab or nivolumab and hyaluronidase-nvhy for the recommended dosage information. | Until disease progression or unacceptable toxicity

Hepatocellular Carcinoma | 34.5 mg orally once daily | Until disease progression or unacceptable toxicity

Extra-pancreatic Neuroendocrine Tumors | Adult Patients and Pediatric Patients 12 years of age and older with bodyweight greater than or equal to 40 kg

34.5 mg orally once daily

Pediatric patients 12 years of age and older with bodyweight less than 40 kg

23 mg orally once daily | Until disease progression or unacceptable toxicity

If converting from CABOMETYX, discontinue CABOMETYX, and use Table 2 to determine OMCAZIO dosage based on dosage equivalence.

CABOMETYX tablets dosage | OMCAZIO capsules dosage

60 mg once daily | 34.5 mg once daily

40 mg once daily | 23 mg once daily

20 mg once daily | 11.5 mg once daily

Withhold OMCAZIO for:

Intolerable Grade 2 adverse reactions

Grade 3 or 4 adverse reactions

Osteonecrosis of the jaw

Thrombotic microangiopathy

Upon resolution/improvement (i.e., return to baseline or resolution to Grade 1) of an adverse reaction, reduce the dose as follows:

The recommended dosage reduction levels for OMCAZIO for adverse reactions are listed in Table 3. …

How to take Cabozantinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Risk of Medication Errors and Important Administration Information: Advise patients that OMCAZIO is not substitutable with other cabozantinib products on a mg-to-mg basis. Advise patients to take OMCAZIO exactly as prescribed

. Advise patients to swallow the capsules whole with water and not to crush, chew, or open the capsules. Advise patients to take OMCAZIO with or without food

.

Hemorrhage: Instruct patients to contact their healthcare provider to seek immediate medical attention for signs or symptoms of unusual severe bleeding or hemorrhage

.

Perforations and fistulas: Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during OMCAZIO treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain

.

Thromboembolic events: Inform patients of the risk of arterial and venous thromboembolic events. Advise patients to immediately contact their health care provider for signs and symptoms suggestive of a blood clot such as dyspnea, chest pain, or localized limb edema

. …

Warnings & precautions

Do not take this medicine if: None.

Cabozantinib is available in multiple dosage forms and strengths. The recommended dosage depends on the specific cabozantinib product prescribed. OMCAZIO is not substitutable on a mg-to-mg basis with other cabozantinib products

. Inappropriate substitution or incorrect conversion of OMCAZIO capsules for another cabozantinib product can:

Increase the risk of serious adverse reactions OR

Reduce its effectiveness.

Confirm that the intended cabozantinib product at the intended dosage and strength is being prescribed and dispensed.

OMCAZIO can cause severe and fatal hemorrhages.

Do not administer OMCAZIO to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena.

The incidence of Grade 3 to 5 hemorrhagic events was 5% in cabozantinib-treated patients in RCC and HCC studies

.

Withhold OMCAZIO for 3 weeks prior to scheduled surgery, including dental surgery to reduce the risk of hemorrhage. Permanently discontinue OMCAZIO for Grade 3 or 4 hemorrhage and prior to surgery as recommended

.

OMCAZIO can cause gastrointestinal (GI) perforations and fistulas.

Fistulas, including fatal cases, occurred in 1% of cabozantinib-treated patients

. GI perforations, including fatal cases, occurred in 1% of cabozantinib-treated patients.

Monitor patients for signs and symptoms of fistulas and perforations, including abscess and sepsis. Permanently discontinue OMCAZIO in patients who experience a Grade 4 fistula or a GI perforation

.

OMCAZIO can cause arterial or venous thromboembolic events.

Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism occurred in 2% of cabozantinib-treated patients. Fatal thromboembolic events occurred in cabozantinib-treated patients

. …

Cabozantinib side effects

The following clinically significant adverse reactions are discussed elsewhere in the labeling:

Hemorrhage

Perforations and Fistulas

Thromboembolic Events

Hypertension and Hypertensive Crisis

Cardiac Failure

Diarrhea

Palmar-Plantar Erythrodysesthesia

Hepatotoxicity

Adrenal Insufficiency

Proteinuria

Thrombotic Microangiopathy

Osteonecrosis of the Jaw

Impaired Wound Healing

Reversible Posterior Leukoencephalopathy Syndrome

Thyroid Dysfunction

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of OMCAZIO (cabozantinib) capsules has been established from adequate and well-controlled studies of CABOMETYX

®(cabozantinib) tablets, which has different recommended dosages than OMCAZIO.

The data described in the WARNINGS AND PRECAUTIONS section and below reflect the adverse reactions of CABOMETYX

®(cabozantinib) tablets in these adequate and well-controlled studies. …

Drug interactions

Strong CYP3A Inhibitors

Avoid coadministration of OMCAZIO with strong CYP3A inhibitors. If coadministration cannot be avoided, reduce the dosage of OMCAZIO

.

Cabozantinib is a CYP3A substrate. Coadministration with a strong CYP3A inhibitor increases cabozantinib exposure

, which may increase the risk of OMCAZIO-associated adverse reactions.

Strong or Moderate CYP3A Inducers

Avoid coadministration of OMCAZIO with strong or moderate CYP3A inducers. If coadministration cannot be avoided, increase the dosage of OMCAZIO

.

Cabozantinib is a CYP3A substrate. Coadministration with a strong CYP3A inducer decreases cabozantinib exposure, which may reduce effectiveness of OMCAZIO

.

About this medicine

OMCAZIO is the laurylsulfate salt of cabozantinib, a kinase inhibitor. Cabozantinib laurylsulfate is described chemically as

N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, Laurylsulfate. The molecular formula is C

40H

50FN

3O

9S and the molecular weight is 767.9 Daltons as laurylsulfate salt. The chemical structure of cabozantinib laurylsulfate salt is:

Cabozantinib laurylsulfate salt is a white to off-white solid that is practically insoluble in aqueous media.

OMCAZIO (cabozantinib) capsules for oral use are supplied as hard gelatin capsules containing 11.5 mg, 23 mg, or 34.5 mg of cabozantinib, which is equivalent to 17.6 mg, 35.2 mg, or 52.8 mg of cabozantinib laurylsulfate, respectively.

OMCAZIO also contains the following inactive ingredient: ammonia solution, ascorbic palmitate, black iron oxide, FD&C Blue #1, gelatin, polyoxyl 32 stearate, potassium hydroxide, propylene glycol, shellac, titanium dioxide, and tocopherol. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c0a58965-24c8-4f4e-ac71-9b36226c7b18. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate